Skip to main content
. 2022 Oct 17;13(1):132–145. doi: 10.1158/2159-8290.CD-22-1074

Figure 3.

Figure 3. Cytotoxic effects of R023 scDb on cells pulsed with a sotorasib–KRAS(G12C) conjugate. A, Schematic representation of the assay. Cells are pulsed with a conjugate or a negative control peptide, and then cocultured with T cells in the presence of scDb. B, Cytotoxic effects of scDbs on Raji cells pulsed with soto-p7, soto-p8, p7WT, or p8WT. C, Cytotoxic effects of the R001 and R023 scDbs on sotorasib-treated Raji cells, which do not possess KRAS(G12C). D, Cytotoxic effects of R023 on OCI-AML3 cells pulsed with soto-p5 and p5WT. Data are from triplicate measurements, and calculated EC50 values are shown. A3-2 is a positive-control antibody that binds to HLA-A3 irrespective of the bound peptide. Data shown are representative of ≥2 equivalent measurements.

Cytotoxic effects of the R023 scDb on cells pulsed with a sotorasib–KRAS(G12C) conjugate. A, Schematic representation of the assay. Cells are pulsed with a conjugate or a negative control peptide, and then cocultured with T cells in the presence of scDb. B, Cytotoxic effects of scDbs on Raji cells pulsed with soto-p7, soto-p8, p7WT, or p8WT. C, Cytotoxic effects of the R001 and R023 scDbs on sotorasib-treated Raji cells, which do not possess KRAS(G12C). D, Cytotoxic effects of R023 on OCI-AML3 cells pulsed with soto-p5 and p5WT. Data are from triplicate measurements, and calculated EC50 values are shown. A3-2 is a positive control (pos. ctrl.) antibody that binds to HLA-A3 irrespective of the bound peptide. Data shown are representative of ≥2 equivalent measurements.